Key points from article :
Lento Bio is developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients.
Presbyopia is an age-related condition that makes it difficult to see near objects.
The company announced today that they have raised $680,000 in funding during their recent oversubscribed seed round.
“This funding will help sustain our preclinical activities through the next major steps,” - Kris Barnes, Lento Bio CEO.
Ichor Life Sciences supports research on therapies targeting advanced glycation end products, linked to aging.
Both companies aim to advance the treatment of degenerative diseases.
“..will advance the study of therapies to target advanced glycation end products – a molecular hallmark of aging”, - Kelsey Moody, CEO and Founder of Ichor Life Sciences.
